Female infertility. Female infertility
Conditions
Interventions
Intervention 1: Intervention group: In intervention group the patient will receive GnRh agonist (Decapeptyl
Ferring, The Netherlands), 0.2 mg sc for triggering final oocyte maturation. Intervention 2: Control group: In control group the patients will receive HCG 10000 IU sc (Institute Biochimique SA (IBSA),
Treatment - Drugs
Intervention group: In intervention group the patient will receive GnRh agonist (Decapeptyl
Ferring, The Netherlands), 0.2 mg sc for triggering final oocyte maturation
Control group: In control group the patients will receive HCG 10000 IU sc (Institute Biochimique SA (IBSA), The Switzerland) for triggering final oocyte maturation
Sponsors
Vice Chancellor of Research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
24 Years to 36 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients who are candidate for IVF/ICSI( Male factor infertility, unexplained infertility, tubal factor infertility), Age below 39 years old, BMI: 18-29, Regular menstrual cycles.Agreement of patient to enrol the research Exclusion criteria: Ovulatory factor infertility, Endometriosis, Uterine anomalies, Age above 39 years old, Non-agreement of patient to enrol the research
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number and Quality of oocytes retrieved in each IVF cycle. Timepoint: on day of ovum pick up. Method of measurement: measuring number and quality of oocytes on the day of pick up by pathologist in lab under microscope and scoring.;Progesterone level. Timepoint: on the day of injection HCG or GnRH agonist(Final Triggering) and rechecked 7 and 14 days after that. Method of measurement: Serum Level, Lab test.;Number and Quality of embryos transferred in IVF cycle. Timepoint: on day of embryo transfer. Method of measurement: measuring number and quality of embryos by pathologist in lab under microscope and grading.;Comparing FSH, LH, Estradiol and HCG in both groups. Timepoint: on days 2 and 6 of menstrual cycle, final oocyte triggering, oocyte retrieval, 7 and 14 days after that oocyte retrieved. Method of measurement: Serum Level, Lab test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of ovarian hyperstimulation syndrome (OHSS). Timepoint: From day of HCG or GnRH agonist injection up to 2 weeks later. Method of measurement: Clinical management of symptoms, Sonography.;Clinical Pregnancy. Timepoint: 16 days after triggering if menstruation was absent. Method of measurement: Serum BHCG and TVS. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. leila Sarikhani
OB. & GYN Department, Shiraz Medical School
Outcome results
None listed